Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ
Market Cap
$1.37B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
646 of 968
Rank in Industry
361 of 556
Largest Insider Buys in Sector
DAWN Stock Price History Chart
DAWN Stock Performance
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Activity of Day One Biopharmaceuticals, Inc.
Over the last 12 months, insiders at Day One Biopharmaceuticals, Inc. have bought $0 and sold $6.67M worth of Day One Biopharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Day One Biopharmaceuticals, Inc. have bought $34.92M and sold $17.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 111,387 shares for transaction amount of $1.11M was made by AI Day1 LLC (10 percent owner) on 2023‑10‑20.
List of Insider Buy and Sell Transactions, Day One Biopharmaceuticals, Inc.
| 2024-11-18 | Sale | HEAD OF R&D | 2,206 0.0022% | $13.21 | $29,142 | +2.61% | ||
| 2024-11-18 | Sale | COO, CFO AND SECRETARY | 2,602 0.0026% | $13.21 | $34,373 | +2.61% | ||
| 2024-11-18 | Sale | CHIEF EXECUTIVE OFFICER | 10,554 0.0106% | $13.21 | $139,420 | +2.61% | ||
| 2024-11-18 | Sale | GENERAL COUNSEL | 3,165 0.0032% | $13.21 | $41,810 | +2.61% | ||
| 2024-11-11 | Sale | HEAD OF R&D | 10,000 0.01% | $16.10 | $160,994 | -13.49% | ||
| 2024-11-08 | Sale | HEAD OF R&D | 18,255 0.0176% | $16.17 | $295,229 | -16.29% | ||
| 2024-11-07 | Sale | HEAD OF R&D | 11,245 0.0113% | $16.03 | $180,287 | -12.94% | ||
| 2024-10-31 | Sale | HEAD OF R&D | 500 0.0006% | $16.02 | $8,010 | -5.37% | ||
| 2024-09-10 | Sale | HEAD OF R&D | 30,000 0.0339% | $14.22 | $426,675 | -1.67% | ||
| 2024-08-16 | Sale | HEAD OF R&D | 2,232 0.0027% | $14.00 | $31,246 | 0.00% | ||
| 2024-08-16 | Sale | COO, CFO AND SECRETARY | 2,633 0.0031% | $14.00 | $36,860 | 0.00% | ||
| 2024-08-16 | Sale | CHIEF EXECUTIVE OFFICER | 10,681 0.0127% | $14.00 | $149,524 | 0.00% | ||
| 2024-08-16 | Sale | GENERAL COUNSEL | 3,202 0.0038% | $14.00 | $44,825 | 0.00% | ||
| 2024-07-16 | Sale | HEAD OF R&D | 20,000 0.0273% | $16.01 | $320,226 | -11.99% | ||
| 2024-06-21 | Sale | director | 10,000 0.012% | $13.19 | $131,877 | +2.96% | ||
| 2024-06-10 | Sale | HEAD OF R&D | 30,000 0.0347% | $12.62 | $378,588 | +11.81% | ||
| 2024-05-16 | Sale | HEAD OF R&D | 2,267 0.0026% | $16.08 | $36,450 | -13.23% | ||
| 2024-05-16 | Sale | CHIEF EXECUTIVE OFFICER | 7,873 0.009% | $16.08 | $126,588 | -13.23% | ||
| 2024-05-16 | Sale | COO, CFO AND SECRETARY | 2,675 0.0031% | $16.08 | $43,011 | -13.23% | ||
| 2024-05-16 | Sale | GENERAL COUNSEL | 3,253 0.0037% | $16.08 | $52,304 | -13.23% |
Insider Historical Profitability
5.29%
| Blackman Samuel C. | HEAD OF R&D | 1064015 1.0551% | $13.62 | 0 | 35 | |
| York Charles N II | COO, CFO AND SECRETARY | 240133 0.2381% | $13.62 | 0 | 24 | |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER | 108377 0.1075% | $13.62 | 0 | 24 | |
| Ramasastry Saira | director | 40485 0.0401% | $13.62 | 0 | 1 | |
| Dubow Adam | GENERAL COUNSEL | 32162 0.0319% | $13.62 | 0 | 5 | |
| AI Day1 LLC | 10 percent owner | 12929322 12.8209% | $13.62 | 8 | 0 | +13.88% |
| Blavatnik Len | 10684638 10.595% | $13.62 | 1 | 0 | +23.65% | |
| Canaan XI L.P. | 10 percent owner | 8464301 8.3933% | $13.62 | 1 | 7 | <0.0001% |
| TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 6120124 6.0688% | $13.62 | 0 | 4 | |
| Atlas Venture Associates Opportunity I, LLC | 766667 0.7602% | $13.62 | 1 | 0 | +23.65% | |
| Gladstone Michael | 766667 0.7602% | $13.62 | 1 | 0 | +23.65% | |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 741396 0.7352% | $13.62 | 2 | 0 | <0.0001% |
| Grant Julie Papanek | director | 330000 0.3272% | $13.62 | 1 | 24 | <0.0001% |
| Josey John A. | director | 72292 0.0717% | $13.62 | 1 | 0 | <0.0001% |
| Becker Daniel J. | director | 5000 0.005% | $13.62 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RA Capital Management, L.P. | $129.02M | 8.94 | 7.81M | 0% | +$0 | 0.13 | |
| Atlas Venture Life Science Advisors Llc | $106.23M | 7.36 | 6.43M | -15.48% | -$19.46M | 9.86 | |
| BlackRock | $83.12M | 5.76 | 5.03M | -1.85% | -$1.56M | <0.01 | |
| The Vanguard Group | $78.87M | 5.46 | 4.77M | +0.1% | +$78,255.24 | <0.01 | |
| Fidelity Investments | $72.76M | 5.04 | 4.4M | +10.99% | +$7.21M | 0.01 | |
| Franklin Templeton Investments | $62.89M | 4.36 | 3.81M | -10.15% | -$7.1M | 0.02 | |
| State Street | $47.82M | 3.31 | 2.89M | -14.36% | -$8.02M | <0.01 | |
| Viking Global Investors | $42.27M | 2.93 | 2.56M | 0% | +$0 | 0.02 | |
| T. Rowe Price | $37.99M | 2.63 | 2.3M | -0.73% | -$280,846.64 | 0.01 | |
| Braidwell Lp | $35.91M | 2.49 | 2.17M | -48.44% | -$33.73M | 2.04 | |
| Goldman Sachs | $35.31M | 2.45 | 2.14M | +0.88% | +$307,965.84 | 0.01 | |
| Janus Henderson | $33.57M | 2.33 | 2.03M | +19.83% | +$5.56M | 0.02 | |
| Deerfield Management | $29.16M | 2.02 | 1.77M | +0.23% | +$68,293.68 | 0.07 | |
| TimesSquare Capital Management LLC | $27.01M | 1.87 | 1.64M | -1.86% | -$510,806.05 | 0.4 | |
| Geode Capital Management | $22.75M | 1.58 | 1.38M | +2.09% | +$464,972.27 | <0.01 | |
| Maverick Capital Ltd | $20.76M | 1.44 | 1.26M | New | +$20.76M | 0.4 | |
| Boxer Capital, LLC | $19.66M | 1.36 | 1.19M | 0% | +$0 | 0.4 | |
| Polar Capital | $19.58M | 1.36 | 1.19M | -14.44% | -$3.3M | 0.11 | |
| Dimensional Fund Advisors | $16.22M | 1.12 | 981,572 | +26.18% | +$3.36M | <0.01 | |
| Driehaus Capital Management LLC | $11.88M | 0.82 | 719,011 | +48.79% | +$3.89M | 0.12 | |
| Parkman Healthcare Partners Llc | $11.43M | 0.79 | 691,812 | +10.56% | +$1.09M | 1.42 | |
| DAFNA Capital Management, LLC | $11.01M | 0.76 | 666,463 | -2.91% | -$330,400.01 | 0.27 | |
| Northern Trust | $9.22M | 0.64 | 558,145 | -3.23% | -$307,387.63 | <0.01 | |
| Sphera Fund | $8.14M | 0.56 | 492,627 | -3.97% | -$336,561.96 | 0.05 | |
| Charles Schwab | $7.56M | 0.52 | 457,652 | +1.04% | +$77,941.36 | <0.01 | |
| Nicholas Investment Partners, L.P. | $5.98M | 0.41 | 361,767 | +19.27% | +$965,577.51 | 0.68 | |
| PFM Health Sciences | $5.87M | 0.41 | 355,251 | -72.75% | -$15.67M | 0.16 | |
| Candriam S C A | $4.79M | 0.33 | 290,014 | 0% | +$0 | 0.03 | |
| Woodline Partners LP | $4.5M | 0.31 | 272,538 | 0% | +$0 | 0.04 | |
| Wellington Management Company | $4.5M | 0.31 | 272,117 | +30.22% | +$1.04M | <0.01 | |
| Schonfeld Group | $3.93M | 0.27 | 237,748 | +32.87% | +$971,607.04 | 0.02 | |
| Morgan Stanley | $3.84M | 0.27 | 232,550 | -30.47% | -$1.68M | <0.0001 | |
| D. E. Shaw & Co. | $3.7M | 0.26 | 224,219 | +14.7% | +$474,619.61 | <0.01 | |
| BNY Mellon | $3.56M | 0.25 | 215,383 | -8.03% | -$310,823.87 | <0.01 | |
| Samsara Biocapital Llc | $3.24M | 0.23 | 196,425 | 0% | +$0 | 0.51 | |
| Rafferty Asset Management Llc | $3.19M | 0.22 | 193,224 | -18.25% | -$712,391.85 | 0.01 | |
| Deutsche Bank | $2.94M | 0.2 | 178,174 | +0.57% | +$16,817.36 | <0.01 | |
| Nuveen | $2.9M | 0.2 | 175,775 | 0% | +$0 | <0.01 | |
| Simplify Asset Management Inc | $2.89M | 0.2 | 175,018 | 0% | +$0 | 0.28 | |
| Citigroup | $2.83M | 0.2 | 171,050 | +71.18% | +$1.17M | <0.01 | |
| Prudential Financial | $2.8M | 0.19 | 169,522 | New | +$2.8M | <0.01 | |
| Laurion Capital Management LP | $2.73M | 0.19 | 164,983 | 0% | +$0 | 0.02 | |
| UBS | $2.71M | 0.19 | 164,018 | +29.52% | +$617,484.48 | <0.01 | |
| Adage Capital Partners Gp L L C | $2.63M | 0.18 | 159,000 | +6% | +$148,680.00 | 0.01 | |
| Marshall Wace | $2.22M | 0.15 | 134,171 | +13.81% | +$268,896.05 | <0.01 | |
| Bank of America | $2.11M | 0.15 | 127,589 | -20.2% | -$533,513.33 | <0.0001 | |
| Macquarie Group | $1.82M | 0.13 | 110,000 | 0% | +$0 | <0.01 | |
| Hudson Bay Capital Management LP | $1.82M | 0.13 | 110,000 | +37.5% | +$495,600.00 | 0.01 | |
| ExodusPoint Capital Management, LP | $1.61M | 0.11 | 97,621 | +138.66% | +$937,156.29 | 0.02 | |
| Swiss National Bank | $1.58M | 0.11 | 95,400 | 0% | +$0 | <0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.